We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

25 hedge funds and large institutions have $833K invested in Bellerophon Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

32% more funds holding

Funds holding: 19 → 25 (+6)

30% less capital invested

Capital invested by funds: $1.18M → $833K (-$349K)

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Holders
25
Holders Change
+6
Holders Change %
+31.58%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
8
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$28.7K
2
Millennium Management
Millennium Management
New York
+$23.5K
3
E
Ergoteles
New York
+$15.2K
4
Jane Street
Jane Street
New York
+$14.1K
5
NAM
NTV Asset Management
West Virginia
+$12.9K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$204K
2
Renaissance Technologies
Renaissance Technologies
New York
-$25K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$16K
4
Wells Fargo
Wells Fargo
California
-$9.21K
5
TI
Telemetry Investments
New York
-$3.58K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
1
Wells Fargo
California
$172K -$9.21K -8,998 -4%
Renaissance Technologies
2
Renaissance Technologies
New York
$155K -$25K -24,392 -12%
Vanguard Group
3
Vanguard Group
Pennsylvania
$131K -$204K -199,384 -58%
BlackRock
4
BlackRock
New York
$90.6K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$57K -$163 -159 -0.2%
TI
6
Telemetry Investments
New York
$40K -$3.58K -3,500 -7%
Northern Trust
7
Northern Trust
Illinois
$25.3K – – –
HF
8
HRT Financial
New York
$25K +$28.7K +28,035 New
SC
9
Sepio Capital
Utah
$21.4K – – –
Millennium Management
10
Millennium Management
New York
$21K +$23.5K +22,944 New
State Street
11
State Street
Massachusetts
$19.2K – – –
Tudor Investment Corp
12
Tudor Investment Corp
Connecticut
$18K – – –
E
13
Ergoteles
New York
$13.4K +$15.2K +14,891 New
Jane Street
14
Jane Street
New York
$12.4K +$14.1K +13,762 New
NAM
15
NTV Asset Management
West Virginia
$11.3K +$12.9K +12,605 New
DWM
16
Destination Wealth Management
California
$9K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$5K -$1.73K -1,689 -22%
UBS Group
18
UBS Group
Switzerland
$2.07K +$2.35K +2,297 New
Morgan Stanley
19
Morgan Stanley
New York
$1.33K +$7 +7 +0.5%
US Bancorp
20
US Bancorp
Minnesota
$1.1K – – –
Osaic Holdings
21
Osaic Holdings
Arizona
$1K – – –
Northwestern Mutual Wealth Management
22
Northwestern Mutual Wealth Management
Wisconsin
$450 – – –
FGAM
23
Financial Gravity Asset Management
Texas
$50 +$1 +1 New
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$16K -14,663 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$178 -174 -69%
1
2

BLPH Hedge Fund Activity: Q4 2022 in Review

25 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2022, worth a combined $833K — down 30% from $1.18M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BLPH positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 8 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $28.7K. The largest seller was Vanguard Group, cutting an estimated $204K.

  • 25 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2022, up from 19 in Q3 2022.
  • Funds reported $833K of Bellerophon Therapeutics, Inc. stock for Q4 2022, down 30% quarter-over-quarter.
  • 7 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2022 and 1 closed out, a net change of +6 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q4 2022 was HRT Financial, an estimated $28.7K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $204K sold.

Based on aggregated 13F filings for Q4 2022.